Articles in this Series –
- Details on 46 Approved Cancer Targeting Antibodies.
- 112 Monoclonal Antibodies in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication.
- 200 Monoclonal Antibodies in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication.
- Bispecific Antibodies in Active Clinical Development – Developers, Pipeline, Targets & Cancer Indication.
- Bispecific Antibodies in Active Preclinical Development – Developers, Pipeline, Targets & Cancer Indication.
- Antibody Drug Conjugates in Active Clinical Development – Developers, Pipeline, Targets & Cancer Indication.
- Antibody Drug Conjugates in Active Preclinical Development – Developers, Pipeline, Targets & Cancer Indication.
Cancer Targeting Antibodies in Development
Approved Monoclonal Antibodies for Cancer Treatment
In 1986, muromonab-CD3 (OKT3) wins the first therapeutic monoclonal antibody approval from the US FDA, which works as an immunosuppressive for the prevention of transplant rejection. Since from past more than three decades from the first approval, till now more than 100 antibodies are approved by US FDA, which...
Read more
